Denosumab for treating giant cell tumor of bone

Bibliography

• Athanassou NA, Bensal M, Forsyth R, et al. Giant cell tumor of bone. IARC Press 2013:321-4
   Google Scholar
• Balke M, Schremper L, Gebert C, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008;134:969-78
   PubMed Web of Science ®Google Scholar
• van der Heijden L, Dijkstra PD, van de Sande MA, et al. The clinical approach toward giant cell tumor of bone. Oncologist 2014;19(5):550-61
   PubMed Web of Science ®Google Scholar
• Raskin KA, Schwab JH, Mankin HJ, et al. Giant cell tumor of bone. J Am Acad Orthop Surg 2013;21:118-26
   PubMed Web of Science ®Google Scholar
• Chakarun CJ, Forrester DM, Gottsegen CJ, et al. Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics 2013;33:197-211
   PubMed Web of Science ®Google Scholar
• Campanacci M, Baldini N, Boriani S, et al. Giant cell tumor of bone. J Bone Jont Surg Am 1987;69:106-14
   PubMed Web of Science ®Google Scholar
• Siebenrock KA, Unni KK, Rock MG. Giant-cell tumor of bone metastasising to the lungs. A long-term follow-up. J Bone Joint Surg Br 1998;80:43-7
   PubMed Web of Science ®Google Scholar
• Tubbs WS, Brown LR, Beabout JW, et al. Benign giant-cell tumor of bone with pulmonary metastases: Clinical findings and radiologic appearance of metastases in 13 cases. AJR Am J Roentgenol 1992;158:331-4
   PubMed Web of Science ®Google Scholar
• Dominkus M, Ruggieri P, Bertoni F, et al. Histologically verified lung metastases in benign giant cell tumors—14 cases from a single institution. Int Orthop 2006;30:499-504
   PubMed Web of Science ®Google Scholar
• Rock MG, Pritchard DJ, Unni KK. Metastases from histologically benign giant-cell tumor of bone. J Bone Joint Surg Am 1984;66:269-74
   PubMed Web of Science ®Google Scholar
• Kay RM, Eckardt JJ, Seeger LL, et al. Pulmonary metastasis of benign giant cell tumor of bone. Six histologically confirmed cases, including one of spontaneous regression. Clin Orthop Relat Res 1994;219:230
   Google Scholar
• Szendroi M. Giant-cell tumor of bone. J Bone Joint Surg Br 2004;86:5-12
   PubMed Web of Science ®Google Scholar
• Kitazawa S. Kitazawa R. rank ligand is a prerequisite for cancer- associated osteolytic lesions. J Pathol 2002;198:228-36
   PubMed Web of Science ®Google Scholar
• Akiyama T, Choong PF, Dass CR. rank-Fc inhibits malignancy via inhibiting Erk activation and evoking caspase-3 – mediated anoikis in human osteosarcoma cells. Clin Exp Metastasis 2010;27:207-15
   PubMed Web of Science ®Google Scholar
• Akiyama T, Dass CR, Shinoda Y, et al. Systemic rank-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts. J Pharm Pharmacol 2010;62:470-6
   PubMed Web of Science ®Google Scholar
• Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8
   PubMed Web of Science ®Google Scholar
• ESMO/European Sarcoma Network Working Group Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii100-9
   PubMedGoogle Scholar
• Biermann JS. Updates in the treatment of bone cancer. J Natl Compr Canc Netw 2013;11(Suppl 5):681-3
   PubMed Web of Science ®Google Scholar
• Murphey MD, Nomikos GC, Flemming DJ, et al. From the archives of AFIP. Imaging of giant cell tumor and giant cell reparative granuloma of bone: Radiologic-pathologic correlation. Radiographics 2001;21:1283-309
   PubMed Web of Science ®Google Scholar
• Hemingway F, Taylor R, Knowles HJ, et al. RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone 2011;48:938-44
   PubMed Web of Science ®Google Scholar
• Wu PF, Tang JY, Li KH. RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects. Tumour Biol 2015;36(2):495-501
   PubMed Web of Science ®Google Scholar
• Hemingway F, Kashima TG, Mahendra G, et al. Smooth muscle actin expression in primary bone tumors. Virchows Arch 2012;460:525-34
   PubMed Web of Science ®Google Scholar
• Thomas DM. RANKL, denosumab, and giant cell tumor of bone. Curr Opin Oncol 2012;24:397-403
   PubMed Web of Science ®Google Scholar
• Roux S, Amazit L, Meduri G, et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 2002;117:210-16
   PubMed Web of Science ®Google Scholar
• Morgan T, Atkins GJ, Trivett MK, et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 2005;167:117-28
   PubMed Web of Science ®Google Scholar
• Atkins GJ, Kostakis P, Vincent C, et al. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006;21(9):1339-49
   PubMed Web of Science ®Google Scholar
• Liao TS, Yurgelun MB, Chang SS, et al. Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res 2005;23:203-9
   PubMed Web of Science ®Google Scholar
• Clézardin P. The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: Physiopathology and clinical implications [in French] Bull Cancer. 2011;98:837-46
   Google Scholar
• Forsyth RG, De Boeck G, Baelde JJ, et al. CD33+ CD14- phenotype is characteristic of multinuclear osteoclast-like cells in giant cell tumor of bone. J Bone Miner Res 2009;24:70-7
   PubMed Web of Science ®Google Scholar
• Maggiani F, Forsyth R, Hogendoorn PC, et al. The immunophenotype of osteoclasts and macrophage polykaryons. J Clin Pathol 2011;64:701-5
   PubMed Web of Science ®Google Scholar
• Rao UN, Goodman M, Chung WW, et al. Molecular analysis of primary and recurrent giant cell tumors of bone. Cancer Genet Cytogenet 2005;158:126-36
   PubMed Web of Science ®Google Scholar
• Gorunova L, Vult von Steyern F, Storlazzi CT, et al. Cytogenetic analysis of 101 giant cell tumors of bone: Nonrandom patterns of telomeric associations and other structural aberrations. Genes Chromosomes Cancer 2009;48:583-602
   PubMed Web of Science ®Google Scholar
• Shehadeh A, Noveau J, Malawer M, et al. Late complications and survival of endoprosthetic reconstruction after resection of bone tumors. Clin Orthop Relat Res 2010;468:2885-95
   PubMed Web of Science ®Google Scholar
• Forsyth RG, De Boeck G, Bekaert S, et al. Telomere biology in giant cell tumor of bone. J Pathol 2008;214:555-63
   PubMed Web of Science ®Google Scholar
• Schwartz HS, Dahir GA, Butler MG. Telomere reduction in giant cell tumor of bone and with aging. Cancer Genet Cytogenet 1993;71:132-8
   PubMed Web of Science ®Google Scholar
• Panagopoulos I, Mertens F, Domanski HA, et al. No EWS/FLI1 fusion transcripts in giant-cell tumors of bone. Int J Cancer 2001;93:769-72
   PubMed Web of Science ®Google Scholar
• Behjati S, Tarpey PS, Presneau N, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 2013;45:1479-82
   PubMed Web of Science ®Google Scholar
• Moskovszky L, Szuhai K, Krenács T, et al. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis. Genes Chromosomes Cancer 2009;48:468-79
   PubMed Web of Science ®Google Scholar
• Antal I, Sápi Z, Szendröi M. The prognostic significance of DNA cytophotometry and proliferation index (Ki-67) in giant cell tumors of bone. Int Orthop 1999;23:315-19
   PubMed Web of Science ®Google Scholar
• Oda Y, Sakamoto A, Saito T, et al. Secondary malignant giant-cell tumor of bone: Molecular abnormalities of p53 and H-ras gene correlated with malignant transformation. Histopathology 2001;39:629-37
   PubMed Web of Science ®Google Scholar
• Saito T, Mitomi H, Izumi H, et al. A case of secondary malignant giant-cell tumor of bone with p53 mutation after long-term follow-up. Hum Pathol 2011;42:727-33
   PubMed Web of Science ®Google Scholar
• Wang H, Wan N, Hu Y. Giant cell tumor of bone: A new evaluating system is necessary. Int Orthop 2012;36:2521-7
   PubMed Web of Science ®Google Scholar
• Miller G, Bettelli G, Fabbri N, Capanna R. Curettage of giant cell tumor of bone. Introduction—material and methods. Chir Organi Mov 1990;75(Suppl 1):203
   PubMedGoogle Scholar
• Klenke FM, Wenger DE, Inwards CY, et al. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011;469:591-9
   PubMed Web of Science ®Google Scholar
• Blackley HR, Wunder JS, Davis AM, et al. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 1999;81:811-20
   PubMed Web of Science ®Google Scholar
• Kivioja AH, Blomqvist C, Hietaniemi K, et al. Cement is recommended in intralesional surgery of giant cell tumors: A Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 2008;79:86-93
   PubMed Web of Science ®Google Scholar
• Becker WT, Dohle J, Bernd L, et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 2008;90:1060-7
   PubMed Web of Science ®Google Scholar
• Algawahmed H, Turcotte R, Farrokhyar F, et al. High-speed burring with and without the use of surgical adjuvants in the intralesional management of giant cell tumor of bone: A systematic review and meta-analysis. Sarcoma 2010;586090
   PubMedGoogle Scholar
• Errani C, Ruggieri P, Asenzio MA, et al. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev 2010;36:1-7
   PubMed Web of Science ®Google Scholar
• Dufresne A, Derbel O, Cassier P, et al. Giant-cell tumor of bone, anti-RANKL therapy. Bonekey Rep 2012;1:149
   PubMedGoogle Scholar
• Errani C, Ruggieri P, Asenzio MA, et al. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev 2010;36:1-7
   PubMed Web of Science ®Google Scholar
• Klenke FM, Wenger DE, Inwards CY, et al. Giant cell tumor of bone: Risk factors for recurrence. Clin Orthop Relat Res 2011;469:591-9
   PubMed Web of Science ®Google Scholar
• Boons HW, Keijser LC, Schreuder HW, et al. Oncologic and functional results after treatment of giant cell tumors of bone. Arch Orthop Trauma Surg 2002;122:17-23
   PubMed Web of Science ®Google Scholar
• Ghert MA, Rizzo M, Harrelson JM, et al. Giant-cell tumor of the appendicular skeleton. Clin Orthop Relat Res 2002;201:210
   Google Scholar
• Turcotte RE, Wunder JS, Isler MH, et al. Giant cell tumor of long bone: A Canadian Sarcoma Group study. Clin Orthop Relat Res 2002;248-58
   PubMed Web of Science ®Google Scholar
• Ward WGSr, Li GIII. Customized treatment algorithm for giant cell tumor of bone: Report of a series. Clin Orthop Relat Res 2002(397):259-70
   PubMed Web of Science ®Google Scholar
• van der Heijden L, van de Sande MA, Dijkstra PD. Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones. Acta Orthop 2012;83:401-4
   PubMed Web of Science ®Google Scholar
• Mankin HJ, Hornicek FJ. Treatment of giant cell tumors with allograft transplants: A 30-year study. Clin Orthop Relat Res 2005;439:144-50
   PubMed Web of Science ®Google Scholar
• Henderson ER, Groundland JS, Pala E, et al. Failure mode classification for tumor endoprostheses: Retrospective review of five institutions and a literature review. J Bone Joint Surg Am 2011;93:418-29
   PubMed Web of Science ®Google Scholar
• Jeys LM, Suneja R, Chami G, et al. Impending fractures in giant cell tumors of the distal femur: Incidence and outcome. Int Orthop 2006;30:135-8
   PubMed Web of Science ®Google Scholar
• McDonald DJ, Sim FH, McLeod RA, et al. Giant-cell tumor of bone. J Bone Joint Surg Am 1986;68:235-42
   PubMed Web of Science ®Google Scholar
• Siebenrock KA, Unni KK, Rock MG. Giant-cell tumor of bone metastasising to the lungs. A long-term follow-up. J Bone Joint Surg Br 1998;80:43-7
   PubMed Web of Science ®Google Scholar
• Tse LF, Wong KC, Kumta SM, et al. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case–control study. Bone 2008;42:68-73
   PubMed Web of Science ®Google Scholar
• Kaban LB, Troulis MJ, Ebb D, et al. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Maxillofac Surg 2002;60:1103-11
   PubMed Web of Science ®Google Scholar
• Shi W, Indelicato DJ, Reith J, et al. Radiotherapy in the management of giant cell tumor of bone. Am J Clin Oncol 2013;36:505-8
   PubMed Web of Science ®Google Scholar
• Bhatia S, Miszczyk L, Roelandts M, et al. Radiotherapy for marginally resected, unresectable or recurrent giant cell tumor of the bone: A rare cancer network study. Rare Tumors 2011;3:e48
   PubMedGoogle Scholar
• Ruka W, Rutkowski P, Morysiński T, et al. The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. Int J Radiat Oncol Biol Phys 2010;78:494-8
   PubMed Web of Science ®Google Scholar
• Caudell JJ, Ballo MT, Zagars GK, et al. Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 2003;57:158-65
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Spiro IJ, Hug EB, et al. Megavoltage radiation therapy for axial and inoperable giant-cell tumor of bone. J Bone Joint Surg Am 1999;81:1566-73
   PubMed Web of Science ®Google Scholar
• Feigenberg SJ, Marcus RBJr, Zlotecki RA, et al. Radiation therapy for giant cell tumors of bone. Clin Orthop Relat Res 2003;(401):207-16
   Google Scholar
• Malone S, O’Sullivan B, Catton C, et al. Long-term follow-up of efficacy and safety of megavoltage radiotherapy in high-risk giant cell tumors of bone. Int J Radiat Oncol Biol Phys 1995;33:689-94
   PubMed Web of Science ®Google Scholar
• Miszczyk L, Wydmański J, Spindel J. Efficacy of radiotherapy for giant cell tumor of bone: Given either postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys 2001;49:1239-42
   PubMed Web of Science ®Google Scholar
• Nair MK, Jyothirmayi R. Radiation therapy in the treatment of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 1999;43:1065-9
   PubMed Web of Science ®Google Scholar
• Bennett CJJr, Marcus RBJr, Million RR, et al. Radiation therapy for giant cell tumor of bone. Int J Radiat Oncol Biol Phys 1993;26:299-304
   PubMed Web of Science ®Google Scholar
• Schwartz LH, Okunieff PG, Rosenberg A, et al. Radiation therapy in the treatment of difficult giant cell tumors. Int J Radiat Oncol Biol Phys 1989;17:1085-8
   PubMed Web of Science ®Google Scholar
• Mittal S, Goswami C, Kanoria N, Bhattacharya A. Post-irradiation angiosarcoma of bone. J Cancer Res Ther 2007;3:96-9
   PubMedGoogle Scholar
• Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumor of bone: An open-label, phase 2 study. Lancet Oncol 2010;11:275-80
   PubMed Web of Science ®Google Scholar
• Huang L, Xu J, Wood DJ, Zheng MH. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of nf-κB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 2000;156:761-7
   PubMed Web of Science ®Google Scholar
• Branstetter DG, Nelson SD, Manivel JC, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012;18:4415-24
   PubMed Web of Science ®Google Scholar
• Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumor of bone: Interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013;14:901-8
   PubMed Web of Science ®Google Scholar
• Martin-Broto J, Cleeland CS, Glare PA, et al. Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study. Acta Oncol 2014;53(9):1173-9
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Ferrari S, Grimer RJ, et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Muheremu A, Niu X. Pulmonary metastasis of giant cell tumor of bones. World J Surg Oncol 2014;12:261
   PubMed Web of Science ®Google Scholar
• Muheremu A, Huang Z, Niu X. Treatment for giant cell tumor of the spine metastasizing to the lung: A report of two cases and a literature review. Oncol Lett 2015;9(3):1321-6
   PubMed Web of Science ®Google Scholar
• Stadler N, Fingernagel T, Hofstaetter SG, Trieb K. A recurrent giant cell tumor of bone treated with denosumab. Clin Pract 2015;5(1):697
   PubMed Web of Science ®Google Scholar
• Karras NA, Polgreen LE, Ogilvie C, et al. Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl. J Clin Oncol 2013;31(12):e200-2
   PubMed Web of Science ®Google Scholar
• Ulas A, Bulent Akinci M, Silay K, et al. Denosumab: Excellent response of metastatic giant cell tumor of the bone. J BUON 2015;20(2):666-7
   PubMed Web of Science ®Google Scholar
• Mak IW, Evaniew N, Popovic S, et al. A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab. J Bone Joint Surg Am 2014;96:e127
   PubMed Web of Science ®Google Scholar
• Mattei TA, Ramos E, Rehman AA, et al. Sustained long-term complete regression of a giant cell tumor of the spine after treatment with denosumab. Spine J 2014;14:e15-21
   PubMed Web of Science ®Google Scholar
• Matcuk GRJr, Patel DB, Schein AJ, et al. Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy. Skeletal Radiol 2015;44(7):1027-31
   PubMed Web of Science ®Google Scholar
• Bidwell JK, Young JW, Khalluff E. Giant cell tumor of the spine: computed tomography appearance and review of the literature. J Comput Tomogr 1987;11:307-11
   PubMedGoogle Scholar
• Goldschlager T, Dea N, Boyd M, et al. Giant cell tumors of the spine: has denosumab changed the treatment paradigm? J Neurosurg Spine 2015;22(5):526-33
   PubMed Web of Science ®Google Scholar
• Adler RA, Gill RS. Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interv Aging 2011;6:119-24
   PubMed Web of Science ®Google Scholar
• Cavalli L, Brandi ML. Targeted approaches in the treatment of osteoporosis: Differential mechanism of action of denosumab and clinical utility. Ther Clin Risk Manag 2012;8:253-66
   PubMed Web of Science ®Google Scholar
• Denosumab. Summary of product characteristics 2015
   Google Scholar
• Aponte-Tinao LA, Piuzzi NS, Roitman P, Farfalli GL. A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab. Clin Orthop Relat Res 2015; Epub ahead of print
   Web of Science ®Google Scholar
• ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014. [Epub ahead of print]
   Google Scholar